查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494721

吉米沙星全球市场：按形式、症状和销售管道- 预测（2024-2030）

Gemifloxacin Market by Form (Solution, Tablet), Indication (Respiratory Infection, Urinary Tract Infection), Sales Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球吉米沙星市场规模为70559万美元，2024年达74101万美元，2030年达到98509万美元，复合年增长率为4.88%。

吉米沙星是一种属于Fluoroquinolones家族的抗生素，主要用于治疗细菌感染疾病，特别是呼吸道感染疾病，包括慢性支气管炎和肺炎的急性发作。吉米沙星透过抑制 DNA 复製、转录、修復和重组所必需的细菌酶发挥作用，有效阻止细菌生长和扩散。患有呼吸道感染疾病（包括慢性支气管炎和肺炎）的患者数量不断增加，大大增加了对有效治疗方法（包括吉米沙星）的需求。世界对抗生素抗药性日益关注，因此需要更有效的治疗方法。吉米沙星已显示出对其他抗生素抗药性的病原体的功效，因此可能提供一种替代治疗策略。扩大吉米沙星配方和应用的研发活动的增加预计将为市场成长创造机会。

主要市场统计
基准年[2023] 70559万美元
预计年份 [2024] 74101万美元
预测年份 [2030] 98509万美元
复合年增长率（%） 4.88%

区域洞察

由于医疗基础设施的改善以及抗生素核准和使用方面的严格规定，用于治疗细菌感染疾病（吉米沙星）市场在美洲显着增长。对抗生素抗药性的认识也在推动研究，审慎的处方实践是美洲市场成长的基石。在医疗成本上升、人口成长和对呼吸道疾病认知不断提高的推动下，亚太地区吉米沙星市场正在快速成长。中国、日本和印度等国家由于人口众多且获得医疗服务的机会不断增加，因此在这一增长中处于领先地位。然而，不同国家有不同的医疗标准和监管环境，这可能会影响市场动态，包括抗生素的供应和核准。在欧洲、中东和非洲，吉米沙星的市场动态受到强有力的法律规范的影响，特别是在欧洲，该框架确保抗生素的安全分配和处方。欧洲先进的医疗体系和高昂的医疗费用有助于吉米沙星的稳定需求。中东和非洲市场的扩张主要是由于经济波动、获得医疗保健的差异以及一些国家的监管挑战。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在吉米沙星市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对吉米沙星市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对当前吉米沙星市场地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 广谱抗菌特性增加了对吉米沙星的需求
      • 医疗基础设施的支持性改革以增加抗生素的获取
    • 抑制因素
      • 因安全问题而召回产品
    • 机会
      • 吉米沙星生产技术不断进步
      • 製药公司与学术/研究机构之间的合作关係
    • 任务
      • 仿冒品的盛行与製造问题
  • 市场区隔分析
    • 剂型：吉米沙星片剂由于其方便常规门诊使用而越来越多地使用
    • 销售管道：根据医疗保健专业人员的诊断和处方笺，透过医院药房扩大吉米沙星的获取范围
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 吉米沙星市场：依形式

  • 液体剂
  • 药片

第七章 吉米沙星市场：依症状

  • 呼吸道感染
  • 尿道感染

第八章 吉米沙星市场：按销售管道

  • 医院药房
  • 网路商店
  • 零售药房

第九章 美洲吉米沙星市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太吉米沙星市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲吉米沙星市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争场景分析
    • Sun Pharma 与太郎製药签署收购协议
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-5D693B46C82C

[190 Pages Report] The Gemifloxacin Market size was estimated at USD 705.59 million in 2023 and expected to reach USD 741.01 million in 2024, at a CAGR 4.88% to reach USD 985.09 million by 2030.

Gemifloxacin is an antibiotic belonging to the fluoroquinolone class and is primarily prescribed to treat bacterial infections, particularly respiratory infections, including acute bacterial exacerbation of chronic bronchitis and pneumonia. Gemifloxacin works by inhibiting bacterial enzymes that are essential for DNA replication, transcription, repair, and recombination, effectively stopping the bacteria from multiplying and spreading. The rising number of cases involving respiratory tract infections, including chronic bronchitis and pneumonia, significantly contributes to the need for effective treatments, including gemifloxacin. There is a continuous need for more effective treatments due to the growing global concern over antibiotic resistance. Gemifloxacin has shown efficacy against pathogens resistant to other antibiotic options, thus providing an alternative treatment course. The availability of certain side effects and safety concerns hampers the market growth. Rising research & development activities to expand the formulation and application of gemifloxacin are expected to create opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 705.59 million
Estimated Year [2024] USD 741.01 million
Forecast Year [2030] USD 985.09 million
CAGR (%) 4.88%

Regional Insights

In the Americas, the market for gemifloxacin, an antibiotic used to treat bacterial infections, is significantly growing due to its well-established healthcare infrastructure and stringent regulations regarding antibiotic approval and usage. Awareness about antibiotic resistance also drives research, and careful prescription practices create a platform for market growth in the Americas. The Asia-Pacific region is witnessing rapid growth in the gemifloxacin market, which is attributed to increasing healthcare expenditures, a rising population, and heightened awareness of respiratory diseases. Countries including China, Japan, and India are leading this growth due to their large populations and increasing access to healthcare services. However, the variation in healthcare standards and regulatory landscapes across different countries can affect market dynamics, including the availability and approval of antibiotics, including gemifloxacin. In the EMEA region, the market dynamics of gemifloxacin are influenced by a strong regulatory framework, especially in Europe, which ensures that antibiotics are safely distributed and prescribed. Europe's advanced healthcare systems and high healthcare spending contribute to a stable demand for Gemifloxacin. In the Middle East and Africa, the market is growing primarily due to economic variability, differing healthcare access, and regulatory challenges in some countries.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Gemifloxacin Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
      • Supportive reforms in healthcare infrastructure enhancing access to antibiotics
    • Market Restraints
      • Product recalls due to safety concerns
    • Market Opportunities
      • Continuous advancements in production technologies of gemifloxacin
      • Partnerships between pharmaceutical companies and academic or research institutions
    • Market Challenges
      • Prevalence of counterfeit products and production issues
  • Market Segmentation Analysis
    • Form: Growing availability of tablet form of gemifloxacin as it is convenient for regular outpatient use
    • Sales Channel: Growing accessibility of gemifloxacin through hospital pharmacies following a diagnosis and prescription from a healthcare professional
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Gemifloxacin Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Gemifloxacin Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Sun Pharma Finalizes Acquisition Agreement with Taro Pharmaceutical

Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. have officially declared a completed merger agreement. Under this arrangement, Sun Pharma, which is already the majority shareholder of Taro, purchases all outstanding shares of Taro not currently held by Sun Pharma or its affiliates for USD 43.00 per share in cash. This move consolidates Sun Pharma's holdings and simplifies Taro's ownership structure, strengthening its market position in the pharmaceutical industry. [Published On: 2024-01-17]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Gemifloxacin Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Gemifloxacin Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Aurobindo Pharma Limited, BASF SE, Emcure Pharmaceuticals Ltd., Hanmi Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Orchid Chemicals & Pharmaceuticals Ltd., Pfizer Inc., Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Gemifloxacin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Form
    • Solution
    • Tablet
  • Indication
    • Respiratory Infection
    • Urinary Tract Infection
  • Sales Channel
    • Hospital Pharmacy
    • Online Stores
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
      • 5.1.1.2. Supportive reforms in healthcare infrastructure enhancing access to antibiotics
    • 5.1.2. Restraints
      • 5.1.2.1. Product recalls due to safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in production technologies of gemifloxacin
      • 5.1.3.2. Partnerships between pharmaceutical companies and academic or research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Prevalence of counterfeit products and production issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Growing availability of tablet form of gemifloxacin as it is convenient for regular outpatient use
    • 5.2.2. Sales Channel: Growing accessibility of gemifloxacin through hospital pharmacies following a diagnosis and prescription from a healthcare professional
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Gemifloxacin Market, by Form

  • 6.1. Introduction
  • 6.2. Solution
  • 6.3. Tablet

7. Gemifloxacin Market, by Indication

  • 7.1. Introduction
  • 7.2. Respiratory Infection
  • 7.3. Urinary Tract Infection

8. Gemifloxacin Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Stores
  • 8.4. Retail Pharmacy

9. Americas Gemifloxacin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gemifloxacin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gemifloxacin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sun Pharma Finalizes Acquisition Agreement with Taro Pharmaceutical
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GEMIFLOXACIN MARKET RESEARCH PROCESS
  • FIGURE 2. GEMIFLOXACIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GEMIFLOXACIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GEMIFLOXACIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SOLUTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SOLUTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY TABLET, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GEMIFLOXACIN MARKET SIZE, BY TABLET, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GEMIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GEMIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE STORES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 35. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 36. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. BRAZIL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 42. BRAZIL GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. CANADA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 48. CANADA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. MEXICO GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 54. MEXICO GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 60. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 76. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. CHINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 82. CHINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. INDIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 88. INDIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. INDONESIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 94. INDONESIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. JAPAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 100. JAPAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 106. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 112. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 118. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 124. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. TAIWAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 130. TAIWAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. THAILAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 136. THAILAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. VIETNAM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 142. VIETNAM GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. DENMARK GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 156. DENMARK GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. EGYPT GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 162. EGYPT GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. FINLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 168. FINLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 173. FRANCE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 174. FRANCE GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. GERMANY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 180. GERMANY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. ISRAEL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 186. ISRAEL GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. ITALY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 192. ITALY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 198. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. NIGERIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 204. NIGERIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. NORWAY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 210. NORWAY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. POLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 216. POLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. QATAR GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 222. QATAR GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. RUSSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 228. RUSSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 234. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. SPAIN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 246. SPAIN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SWEDEN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 252. SWEDEN GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 258. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. TURKEY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 264. TURKEY GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 282. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023